二甲双胍联用罗格列酮治疗2型糖尿病疗效观察  

Therapeutic effect of the co-administrated metformin and rosiglitazone in treatment of type 2 diabetes mellitus

作　　者：范洪[1] 申虎威[1] 李竞[2] 

机构地区：[1]长治医学院附属和平医院内分泌科,山西046000 [2]武汉大学人民医院内分泌科

出　　处：《中国糖尿病杂志》2008年第5期278-279,共2页Chinese Journal of Diabetes

摘　　要：目的了解二甲双胍联用罗格列酮(RGZ)治疗2型糖尿病(T2DM)的疗效及优点。方法将53例T2DM患者随机分为二甲双胍联用格列吡嗪组(A组)、二甲双胍联用RGZ组(B组),进行6个月治疗,测定治疗前后BP、PG、BMI、HbA1c、Ins、血脂等指标,并计算胰岛素抵抗指数(HOMA-IR)。结果两组治疗均可使BP、PG、BMI、HbA1c及LDL-C下降(P<0.05),但B组同时可使Ins水平下降(P<0.05)、HOMA-IR降低(P<0.01)。结论二甲双胍联用RGZ可改善T2DM患者的糖脂代谢紊乱,并降压、减重,同时改善IR。Objective To study the therapeutic effect of co-administrated metformin and rosiglitazone in the treatment of type 2 diabetes mellitus（T2DM）. Methods 53 patients with T2DM were divided into 2 groups in random： co-administrated glipizide and metformin （group A） and co- administrated metformin and rosiglitazone（group B）. All cases were treated for 6 months. Blood pressure （BP）, blood glucose（BG）, body mass index（BMI）, hemoglobin A1 c （HbA1 c）,insulin, and blood lipid were determined and the HOMA- insulin resistance index （HOMA-IR）was calculated. Results Both treatments were effective on hyperglucose, hypertension, hyperlipidemia and high BMI （P 〈 0. 05-0. 01） , while group B could lower the level of insulin（P〈0.05） and HOMA- IR（P〈0.01）. Conclusions Treatment of co-administrated metformin and rosiglitazone can improve the abnormal carbohydrate and lipid metabolism,higher levels of BP and BMI,and ameliorate insulin resistance.

关 键 词：糖尿病 2型 胰岛素抵抗 罗格列酮 二甲双胍 格列吡嗪 

分 类 号：R587[医药卫生—内分泌]